Inflammation is a normal defensive response to tissue damage caused by physical injury and harmful chemicals and currently, management of this condition is by the non-steroidal anti-inflammatory drugs (NSAIDs), which have various adverse effects. Over activity of the coagulation cascade (hypercoagulation) increases the risk of thrombosis formation leading to thromboembolism which in turn leads to ischemia by blocking blood flow and damaging the organs. Siddha formulations afford an incredible improvement in medical practice against various metabolic and lifestyle disorders. Hence, the present study was to evaluate the preliminary phytochemicals and in vitro anti-inflammatory potential of Tulasi oil (TO) against the HRBC membrane stabilization assay, egg albumin denaturation assay and the in vitro anticoagulant analysis. Tulasi oil appears to contain chemical constituents such as alkaloids, flavonoids, steroids, triterpenoids, tannins, phenols, proteins, anthocyanins and saponins. The concentration of 250 μg/ml of Tulasi oil has exhibited a maximum percentage of haemolysis (86.42 ± 0.25%) and albumin (protein) denaturation (81.15±0.82%) while the same concentration (250 μg/ml) of standard drug of hydrocortisone represented the haemolysis of 88.48 ± 0.33% and Diclofenac sodium showed 87.84±0.67 % of protein denaturation. For anticoagulant activity, the concentration of 20 mg/ml of tulasi oil showed maximum anti-coagulant activity of (1227 sec) and a minimum of 686 sec in 5 mg/ml. The standard drug EDTA and Sodium citrate showed better anti-coagulant activities of more than 30 minutes i,e., 2253 and 2156 minutes, respectively. The result of the work indicates that the polyherbal formulation of Tulasi oil has possessed remarkable in vitro anti-inflammatory and anticoagulant potential and can be applied as an alternative in the treatment of various inflammatory and cardiovascular complications.
Introduction and Aim: Siddha formulations of drugs had been used for hundreds of years in international conventional drugs for his or her capacity fitness benefits. Ganthi Mezhugu (GM) has a wide range of therapeutic properties. The objective of the present research was to establish the safety profile of the experimental drug GM in a rat model by acute and sub-acute oral toxicity, as per OECD regulatory guidelines. Materials and Methods: Acute toxicity testing is done for an animal species to determine the effects of a single dose on that species. In this investigation, acute toxicity was assessed using single oral administrations of 50 mg/kg, 300 mg/kg, and 2000 mg/kg. In the subacute investigation, the test substance GM was repeatedly dosed (4.68, 23.4, and 46.8 mg/kg/day) for 28 days followed by these hematological and biochemical parameters were assessed. Results: The study's findings showed that after administering the test substance GM to experimental animals once or repeatedly, there was no evidence of toxicity and no deaths. The subacute toxicity study's GM treated groups' normal hematological and serological profiles provided additional evidence that the formulation is not harmful. Conclusion: The finding of the study supported the notion that Siddha formulation GM is non-toxic and has a broad spectrum of safety.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.